K2 Therapeutics raises US$50M to build global biotech pipeline from Singapore
Summary
Singapore’s biotech sector has long had the ingredients of a serious life sciences hub: strong universities, public research funding, hospital networks, and a government keen to pull high-value industries into the city-state. What it has had less of is a steady stream of venture-backed drug developers built to compete internationally from day one. K2 Therapeutics […] The post K2 Therapeutics raises US$50M to build global biotech pipeline from Singapore appeared first on e27 .
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For Singapore, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketSingapore
- ImpactMedium (52/100)
- SignalFunding